The National Medical Products Administration (NMPA) of China approved the combination of Bestuzumab (generic name: injection of Vemurafenib) and Keytruda (generic name: injection of Pembrolizumab) for adult patients with locally advanced or metastatic urothelial carcinoma. The new combination therapy will provide an alternative for patients in China with locally advanced or metastatic urothelial carcinoma, replacing the standard platinum-based chemotherapy regimen that has been used for nearly 40 years, becoming a new treatment option.
NMPA批准备思复联合可瑞达用于治疗晚期膀胱癌
The NMPA approved the combination of Bestuzumab and Keytruda for the treatment of advanced bladder cancer.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Investment Course
Choose stocks based on financial reports
Quickly master financial season learning guidelines
When the financial season comes, company stock prices are the most likely to rise and fall, and many excellent investors will see the financial season as a good
How to view Tesla's performance in January 2025? Pay attention to these four key points.
It's earnings season for US stocks again. The performance of giant companies not only affects their own stock prices but also influences the overall trend of th
In 【2024.11】, surged more than 0.04 million times, achieving the title of stock god Buffett! How do you view Berkshire's performance?
When it comes to legendary figures in the investment world, the name of Warren Buffett, the helm of Berkshire Hathaway, is definitely unavoidable. $Berkshire Ha